Atypical antipsychotic drugs, which are more potent direct acting antagonists of brain serotonin (5-HT) 2A than dopamine (DA) D 2 receptors, preferentially enhance DA and acetylcholine (ACh) efflux in the rat medial prefrontal cortex (mPFC) and hippocampus (HIP), compared with the nucleus accumbens (NAc). These effects may contribute to their ability, albeit limited, to improve cognitive function and negative symptoms in patients with schizophrenia. Asenapine (ASE), a new multireceptor antagonist currently in development for the treatment of schizophrenia and bipolar disorder, has complex serotonergic properties based upon relatively high affinity for multiple serotonin (5-HT) receptors, particularly 5-HT 2A and 5-HT 2C receptors. In the current study, the effects of ASE on DA, norepinephrine (NE), 5-HT, ACh, glutamate, and g-aminobutyric acid (GABA) efflux in rat mPFC, HIP, and NAc were investigated with microdialysis in awake, freely moving rats. ASE at 0.05, 0.1, and 0.5 mg/kg (s.c.), but not 0.01 mg/kg, significantly increased DA efflux in the mPFC and HIP. Only the 0.5 mg/kg dose enhanced DA efflux in the NAc. ASE, at 0.1 and 0.5 mg/kg, significantly increased ACh efflux in the mPFC, but only the 0.5 mg/kg dose of ASE increased HIP ACh efflux. ASE did not increase ACh efflux in the NAc at any of the doses tested. The effect of ASE (0.1 mg/kg) on DA and ACh efflux was blocked by pretreatment with WAY100635, a 5-HT 1A antagonist/D 4 agonist, suggesting involvement of indirect 5-HT 1A agonism in both the actions. ASE, at 0.1 mg/kg, increased NE, but not 5-HT, efflux in the mPFC and HIP. ASE, at 0.1 mg/kg (s.c.), had no effect on glutamate and GABA efflux in either the mPFC or NAc. These findings indicate that ASE is similar to clozapine and other atypical antipsychotic drugs in preferentially increasing the efflux of DA, NE, and ACh in the mPFC and HIP compared with the NAC, and suggests that, like these agents, it may also improve cognitive function and negative symptoms in patients with schizophrenia.
INTRODUCTION
Atypical antipsychotics differ from conventional antipsychotic drugs in that they cause fewer extrapyramidal symptoms (EPS), do not produce sustained elevations of serum prolactin levels (with the exception of risperidone and paliperidone), and can improve some domains of cognition in patients with schizophrenia (Meltzer and McGurk, 1999; Harvey and Keefe, 2001; Woodward et al, 2005; Keefe et al, 2007) . The basis for the cognitive impairment in schizophrenia is complex; it has principally been related to diminished or dysregulated brain dopaminergic (Weinberger et al, 1988) , noradrenergic (Arnsten and Li, 2005) , cholinergic (Meltzer and McGurk, 1999; Bymaster et al, 2002) , glutamatergic (Hirsch et al, 1997) , and g-aminobutyric acid (GABA) activity (Benes and Berretta, 2000) , to neuronal or neuropil loss (Selemon and GoldmanRakic, 1999) , and to abnormalities in connectivity (Pantelis et al, 1997; Nakamura et al, 2005) . Thus, the ability of atypical antipsychotic drugs to preferentially increase extracellular efflux of dopamine (DA), norepinephrine (NE), and acetylcholine (ACh) in the medial prefrontal cortex (mPFC) and hippocampus (HIP) has been postulated to contribute to their ability to improve cognition, in schizophrenia, and possibly negative symptoms and depression (Assie et al, 2005; Devoto et al, 2004; Ichikawa et al, 1998; Ichikawa et al, 2002a, b, c; Kuroki et al, 1999; Zhang et al, 2000) . The effects of atypical antipsychotic drugs on glutamatergic transmission has also been suggested to contribute to their ability to improve cognitive impairment in schizophrenia (Konradi and Heckers, 2003; Coyle, 2006) . Acute treatment with clozapine has been reported to enhance extracellular glutamate levels while decreasing GABA efflux in the rat mPFC, in some but not all studies (Bourdelais and Deutch, 1994; Daly and Moghaddam, 1993; Yamamoto and Cooperman, 1994; Heidbreder et al, 2001) . Olanzapine, however, at 5 mg/kg, had no effect on the extracellular levels of glutamate, whereas clozapine, at 10 mg/kg, significantly increased extracellular glutamate levels in the same study (Heidbreder et al, 2001) . Haloperidol has also been reported to decrease extracellular GABA efflux from interneurons in the mPFC (Bourdelais and Deutch, 1994) .
Asenapine (ASE) (Org 5222; trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz [2,3:6,7 ,5]-oxepino- [4,5c] pyrrolidine maleate) is a putative atypical antipsychotic drug (Broekkamp et al, 1990; Bymaster et al, 1996; Costall et al, 1990; De Boer et al, 1990 Shahid et al, 2007) currently being developed for the treatment of schizophrenia and bipolar disorder (Alphs et al, 2007) . Potkin et al (2007) have recently reported that ASE improves positive and negative symptoms in patients with schizophrenia at least as effectively as risperidone (Potkin et al, 2007) .
In vitro and in vivo receptor binding studies have shown that ASE has high affinities for multiple monoamine receptors, including (1) D 1,2,3 and D 4 ; (2) 5-HT 2A, 2C, 1A,1B, 2B, 5A, 6, 7 ; (3) adrenergic a 1A and a 2A,2B,2C ; and (4) histamine H 1 and H 2 receptors, but that it lacks affinity for muscarinic receptors (Bymaster et al, 1996; Cosi and Koek, 2001; Matsubara et al, 1993; Prinssen et al, 2000; Richelson and Souder, 2000; Schotte et al, 1996; Shahid et al, 2007) . In vitro assessments have shown that ASE is an antagonist at all of the monoamine receptors listed above (Shahid et al, 2007) . ASE has approximately 20-fold higher affinity for 5-HT 2A compared with DA D 2 receptors (De Boer et al, 1993; Schotte et al, 1996; Shahid et al, 2007) . Shahid et al (2007) reported the pK i for ASE for the 5-HT 2A receptor as 10.15, and for the D2L, 8.90, using cloned human receptors stably expressed in mammalian cell lines. The occupancy in the rat brain of cortical 5-HT 2A receptors by ASE is also about 20-fold higher than that of striatal D 2 receptors (Schotte et al, 1996) . The relatively high occupancy of 5-HT 2A compared with the D 2 receptor may be critically important for some atypical antipsychotic drug actions, such as low EPS and efficacy in treatment-resistant schizophrenia (Meltzer et al, 1989 (Meltzer et al, , 2003 (Meltzer et al, , 2008 . This profile has also been proposed as an important component of the preferential release of cortical DA by relatively specific ligands for these receptors, for example, M 100907, SR 43469B, or ACP-103, and haloperidol (Liegeois et al, 2002; Bonaccorso et al, 2002; Li et al, 2005) , as well as clozapine, olanzapine, risperidone, and other atypical antipsychotic drugs, which are more potent 5-HT 2A than D 2 antagonists (Kuroki et al, 1999) .
The ability of WAY100635, a silent 5-HT 1A antagonist and D 4 agonist (Chemel et al, 2006) , to block most or all of the ability of the atypical antipsychotic drugs to enhance cortical DA (Ichikawa et al, 2001; Li et al, 2004) , as well as, for some, for example, quetiapine, ACh efflux (Ichikawa et al, 2002a, c; Sato et al, 2007) , suggests that these effects of the atypical antipsychotic drugs are due in part to indirect or direct 5-HT 1A agonism (Ichikawa et al, 2001; Meltzer et al, 2003; Li et al, 2004) . Risperidone and olanzapine are atypical antipsychotic drugs whose effects on cortical DA efflux are blocked by WAY100635, but which themselves are not 5-HT 1A agonists. Aripiprazole, bifeprunox, clozapine, quetiapine, and ziprasidone, on the other hand, are 5-HT 1A partial agonists (Cosi and Koek, 2001 ). We, therefore, sought to characterize the effect of WAY100635 on ASEinduced increases in DA and ACh efflux in mPFC. We also sought to characterize the effect of ASE on the efflux of cortical 5-HT, glutamate, and GABA, as there are limited data on the ability of atypical antipsychotic drugs to affect the efflux of these important neurotransmitters.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley albino rats (Zivic-Miller Laboratories, Porterville, PA) weighing 250-300 g were used throughout the study. They were housed two per cage in a controlled 12:12-h light-dark cycle under constant temperature at 221C, with free access to food and water.
Surgery and Microdialysis
Rats were anesthetized with a combination of intraperitoneal chloral hydrate (172 mg/kg) and pentobarbital (35.6 mg/kg), and mounted in a stereotaxic frame (Stoetling, Wood Dale, IL). A stainless steel guide cannula (21 G) with a dummy probe was placed and fixed by cranioplastic cement (Plastics One, Roanoke, VA) onto the cortex, dorsal to the mPFC. The stereotaxic coordinates for the implanted probe were A, + 3.2 mm; L, À0.8 mm (101 inclination); V, À5.5 mm, relative to the bregma. The coordinates for HIP and nucleus accumbens (NAc) were A, À5.6 mm; L, + 5 mm; V, À7 mm; and A, + 2 mm; L, + 1.5 mm; V, À7.5 mm, respectively. The incisor bar level was À3 mm, according to the atlas of Paxinos and Watson (1986) . Concentric-shaped dialysis probes were constructed as described elsewhere (Ichikawa et al, 2001) . A hollow-fiber dialysis membrane (polyacrylonitrile/sodium methylsulfonate polymer, 310 mm, o.d., 220 mm, i.d., molecular weight cut-off 40 000Da; AN69 HF; Hôpital SA, Lyon, France) was used, with 2 mm of non-glued surface exposed for dialyzing. A total of 3-5 days after cannulation, dual dialysis probes were implanted into the rat mPFC and HIP/NAc under light anesthesia with methylsulfonate (Metofane; Pitman-Moore, Mundelein, IL). For systemic administration of drugs or the vehicle, a microbore Tygon tubing (TGY-010, 0.03 inches, o.d., 0.01 inches, i.d.; Small Parts Inc., Miami Lakes, FL) catheter was implanted subcutaneously into the intrascapular space. Rats were then housed individually in dialysis cages, with overnight perfusion (0.3 ml/min) of the probe, with the perfusion rate increased to 1.5 ml/min on the morning of the day of dialysis. After 1 h of perfusion at 1.5 ml/min, dialysate samples were collected every 30 min for measuring dialysate neurotransmitter concentrations. The perfusion medium was Dulbecco's phosphate-buffered saline solution (Sigma, St Louis, MO), including Ca 2 + (138 mM NaCl, 8.1 mM Na 2 HPO 4 , 2.7 mM KCl, 1.5 mM KH 2 PO4, 0.5 mM MgCl, 1.2 mM CaCl 2 , pH ¼ 7.4). After stable baseline values were obtained in the dialysates, each Effect of asenapine on neurotransmitter efflux in the rat brain M Huang et al drug or vehicle was administered subcutaneously. The effect of the drug on neurotransmitter release was monitored for another 180 min. Locations of dialysis probes were verified at the end of each experiment by manual brain dissection and using 100-mm brain slices (OTS-4000; FHC Inc., Bowdoinham, ME). The procedures used in this experiment were approved by the Institutional Animal Care and Use Committee of Vanderbilt University, Nashville, TN.
Biochemical Assays
DA, NE, serotonin, and ACh analysis. All samples were directly applied onto a high-performance liquid chromatography (HPLC) system with electrochemical detection. DA and NE were simultaneously separated on a reversed-phase column (Xtera RP18, 3 mm, 2.1 Â 100 mm; Waters Co., Milford, MA). The mobile phase consisted of buffer (24 mM anhydrous citric acid, 48 mM sodium acetate trihydrate, 2 mM sodium dodecylsulfate, 0.5 mM EDTA2Na), acetonitrile, and methanol in a ratio of 88:8:4, respectively, and adjusted to pH 4.8 with sodium hydroxide. The flow rate was 0.3 ml/min. The potentials for Coulochem microdialysis electrode (ESA 5014B; ESA Biosciences Inc., Chelmsford, MA) were À100 mV and 180 mV vs an Ag/AgCl reference electrode. The retention times for NE and DA were 4.6 and 13 min, respectively. The method for determination of dialysate 5-HT has been described previously (Ichikawa et al, 1998) . The method for determination of dialysate ACh, without addition of a cholinesterase inhibitor, has been described previously (Ichikawa et al, 2002b) .
Glutamate and GABA analysis. The stock-derivatizing agent OPA (o-phthalaldehyde, 3.0 mg; Sigma-Aldrich, St Louis, MO) was dissolved in 140 ml absolute ethanol (HPLC grade), to which was added 140 ml sodium sulfite (Na 2 SO 3 , 1 mM) and 2.4 ml of sodium tetraborate buffer at pH 10.4 (NaBH 4 , 1 mM). The working OPA consisted of 0.5 ml stock OPA, 0.5 ml Na 2 SO 3 , and 4 ml NaBH 4 (pH 10.4). b-Aminobutyric acid dissolved in water constituted the internal standard. The reaction of 5 ml internal standard, 20 ml sample, and 5 ml working OPA solution proceeded at room temperature for 30 min before injection into the HPLC system. The column system consisted of a small column (XTrra reverse-phase C18, 2.1 Â 10 mm, column A; Waters Co.) and a main reverse-phase column (Nova-Pak C18, 3.9 Â 300 mm, 5 mm, column B; Waters Co.) kept at 361C when in use. The mobile phase consisted of 83.5% (v/ v) of buffer (0.1 M sodium dihydrogen phosphate dehydrate, 2 mM tetrabutylammonium phosphate, and 1 mM EDTA, adjusted to pH 4 with 1 M phosphoric acid) and 16.5% of acetonitrile, perfused at a flow rate of 0.9 ml/min by a gradient liquid chromatograph pump (LC-10AD; Shimadzu Corp., Kyoto, Japan). A high-density glassy carbon working electrode combined with an Ag/AgCl reference electrode was operated at + 0.58 V. A Rheodyne injection valve with a 20-ml sample loop with auto-sampler was used to inject the samples. Column A was outside the main system and perfused by mobile phase at 0.1 ml/min, with a Waters HPLC pump. At sample injection, the flow rate was raised to 0.25 ml/min, and 45 s later the small column was connected to main column B for a minute.
Column A was then isolated and perfused with 50% buffer and 50% acetonitrile for 10 min, and eluted with the mobile phase for a further 5 min. The flow rate of column A was then decreased to 0.1 ml/min, prior to the next sample injection.
Drugs ASE (Org 5222; trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7,5]-oxepino-[4,5c]pyrrolidine maleate; Organon, Lanarkshire, UK) and the 5-HT 1A blocker WAY100635 (Wyeth, Philadelphia, PA) were dissolved in deionized water. Vehicle or drug was administered subcutaneously through the implanted catheter in a volume of 1 ml/kg. WAY100635 was given 30 min prior to ASE. The doses of ASE were selected based on published in vivo behavioral and receptor studies (De Boer et al, 1993; Schotte et al, 1996) .
Data Analysis
All dialysis probe placements were checked after killing the rats. Only results derived from rats with correctly positioned probes were included in the data analysis. Three rats, which were sedated following surgery, were not studied. The mean value of three consecutive stable samples prior to drug injection was set at 100% and considered the predrug basal level. Basal extracellular levels of each neurotransmitter in the mPFC, HIP, and NAC were compared by one-way analysis of variance (ANOVA). The time-dependent effect of drugs on each neurotransmitter in the three regions was analyzed using a repeated-measure ANOVA, with treatment group as a fixed factor and time as the within-subject factor. The response area under the curve (AUC) was calculated by the trapezoid rule, using data following injection of the vehicle or drug. Two-way ANOVA was used to compare the effect of treatment on AUC for each neurotransmitter across the three regions. ANOVA was followed by the least-square significant difference post hoc pairwise comparison procedure. The level of significance was set at po0.05. All analyses were performed using SASt (SAS Institute Inc., Cary, NC, USA) statistical software.
RESULTS
Baseline Extracellular DA, NE, Serotonin, ACh, Glutamate, and GABA Levels in the Cortex, HIP, and NAc
One-way ANOVA showed no significant differences among the treatment groups regarding baseline extracellular DA, ACh, NE, 5-HT, glutamate, and GABA levels in the three brain regions studied. Baseline extracellular DA levels in all rats in this study were 0.12 ± 0.02 nM in the mPFC (F ¼ 1.16, p ¼ 0.36, n ¼ 38), 0.15±0.03 nM in the HIP (F ¼ 2.70, p ¼ 0.08, n ¼ 38), and 0.75±0.06 nM in the NAc (F ¼ 2.24, p ¼ 0.16, n ¼ 20). Baseline NE levels were 0.19 ± 0.03 nM in the mPFC (F ¼ 0.84, p ¼ 0.46, n ¼ 20) and 0.12 ± 0.02 nM in the HIP (F ¼ 2.64, p ¼ 0.09, n ¼ 19). Baseline 5-HT levels in the dialysates were 0.12 ± 0.01 nM in the mPFC (F ¼ 2.32, p ¼ 0.18, n ¼ 15) and 0.13 ± 0.02 nM in the HIP (F ¼ 1.77, p ¼ 0.24, n ¼ 15). Baseline ACh levels were 0.58±0.14 nM in the mPFC (F ¼ 2.77, p ¼ 0.08, n ¼ 28), 0.47 ± 0.09 nM in the HIP (F ¼ 3.00, p ¼ 0.10, n ¼ 23), and 0.44 ± 0.17 nM in the NAc (F ¼ 1.76, p ¼ 0.24, n ¼ 21). Baseline extracellular glutamate levels were 2.38 ± 0.60 mM in the mPFC (F ¼ 0.85, p ¼ 0.40) and 2.46 ± 0.67 mM in the NAc (F ¼ 1.69, p ¼ 0.26, both n ¼ 10). Baseline GABA levels were 0.04±0.01 mM in the mPFC (F ¼ 0.57, p ¼ 0.48) and 0.05 ± 0.01 mM in the NAc (F ¼ 0.35, p ¼ 0.58, both n ¼ 10). Vehicle administration did not affect extracellular baseline levels of these neurotransmitters, in these regions.
Effect of ASE on DA Efflux in the MPFC, HIP, and NAc ASE increased extracellular DA in the mPFC, HIP, and NAC (Figure 1 ). Repeated-measure ANOVA of mPFC data showed significant overall group (F ¼ 7.31, p ¼ 0.0001) and time effects (F ¼ 2.66, p ¼ 0.02). The group Â time effect was not significant. Post hoc analysis revealed that ASE at 0.05 mg/kg (p ¼ 0.004), ASE at 0.1 mg/kg (p ¼ 0.005), and ASE at 0.5 mg/ kg (p ¼ 0.0003) were significantly different from the vehicle, whereas ASE at 0.01 mg/kg differed from the higher doses but not the vehicle. For the HIP, both overall group (F ¼ 4.32, p ¼ 0.01) and time (F ¼ 2.40, p ¼ 0.03) effects were significant, but the group Â time interaction was not. Post hoc analysis showed that ASE at 0.05 mg/kg (p ¼ 0.03) and ASE at 0.5 mg/kg (p ¼ 0.004) differed significantly from the vehicle; ASE at 0.1 mg/kg differed at the trend level (p ¼ 0.09); ASE at 0.01 mg/kg did not differ from the vehicle, but was significantly different from the other doses studied. For the NAc, the group Â time interaction was significant (F ¼ 1.84, p ¼ 0.03). The time effect was not significant, but the overall group effect was (F ¼ 5.93, p ¼ 0.01). Post hoc analysis revealed that ASE at 0.5 mg/kg was significantly different from the vehicle (p ¼ 0.002), ASE at 0.1 mg/kg (p ¼ 0.005), and ASE at 0.05 mg/kg (p ¼ 0.01). The response AUC (Figure 1 ) was significantly different among the treatment groups for each region, mPFC (F ¼ 6.99, p ¼ 0.001), HIP (F ¼ 4.69, p ¼ 0.007), and NAC (F ¼ 5.70, p ¼ 0.01). Post hoc analysis showed essentially the same group differences within region as the repeated-measure ANOVA reported above. P-values for differences among the response AUCs are given in the legend to 
increases on DA efflux in the mPFC compared with in the NAC; there were no differences between the effects of ASE on DA efflux in the mPFC and HIP at any of the doses studied.
Effects of ASE on ACh Efflux in the mPFC, HIP, and NAc ASE increased extracellular ACh in the mPFC and HIP but not in the NAC (Figure 2) . Repeated-measure ANOVA of mPFC ACh data showed significant overall group (F ¼ 7.94, p ¼ 0.0004) and time effects (F ¼ 2.43, p ¼ 0.03). The group Â time effect was not significant. Post hoc analysis revealed that ASE at 0.05 mg/kg (p ¼ 0.04), ASE at 0.1 mg/kg (p ¼ 0.00), and ASE at 0.5 mg/kg (p ¼ 0.002) were significantly different from the vehicle, whereas ASE at 0.01 mg/kg differed from the higher doses, but not the vehicle. For the HIP, both the overall group (F ¼ 3.43, p ¼ 0.03) and time (F ¼ 3.44, p ¼ 0.004) effects were significant, but the grouptime interaction was not. Post-hoc analysis showed that ASE at 0.5 mg/kg differed significantly from the vehicle (p ¼ 0.005), from ASE at 0.01 mg/kg (p ¼ 0.01), and ASE at 0.05 mg/kg (p ¼ 0.04). The response AUC (Figure 2 ) was significantly different among the treatment groups for each region, mPFC (F ¼ 7.02, p ¼ 0.001) and HIP (F ¼ 3.99, p ¼ 0.02) but not the NAC. Post hoc analysis showed essentially the same group differences within region as the repeated-measure ANOVA reported above. P-values for differences among the response AUCs within regions are given in the legend to Figure 2 . Two-way ANOVA was used to compare the treatment groups in the mPFC and HIP. The interaction of region and treatment was not significant. The main effect of group (dose), was significant for both regions (F ¼ 10.08, p ¼ 0.0001). There was no significant effect for region at any of the doses studied.
Effect of Pretreatment with WAY100635 on ASEInduced DA and ACh Release in the mPFC and HIP WAY100635 (0.2 mg/kg, s.c.) alone had no significant effect on DA or ACh efflux in the mPFC or the HIP (Figure 3) . Pretreatment with WAY100635 significantly attenuated the increased DA efflux induced by ASE at 0.1 mg/kg in both the mPFC (F 1,9 ¼ 20.56, Po0.001) and HIP (F 1,9 ¼ 8.47, p ¼ 0.005). WAY100635 also significantly inhibited the effect of ASE on ACh efflux in the mPFC (F 1,9 ¼ 16.58, Po0.001). Post hoc analysis results showed the same group differences within region as the repeated-measure ANOVA reported above. P-values for differences among the response AUCs are given in the legend to Figure 4 . Two-way ANOVA was used to compare the treatment group across the three regions. The interaction of region and treatment was not significant. The main effects of region, regardless of dose (F ¼ 3.20, p ¼ 0.05), and treatment group, regardless of region (F ¼ 15.35, p ¼ 0.0001), were significant. ASE at 0.05 mg/kg (p ¼ 0.03) and ASE at 0.1 mg/ kg (p ¼ 0.02), but not ASE at 0.5 mg/kg (p ¼ 0.09), produced greater increases on DA efflux in the mPFC compared with in the NAc; there were no differences between the effects of ASE on DA efflux in the mPFC and HIP at any of the doses studied.
Effect of ASE on Serotonin Efflux in the mPFC and HIP
As shown in Figure 5 , ASE, at 0.05 and 0.1 mg/kg, had no effect on 5-HT efflux in either the mPFC or HIP.
Effect of ASE on Glutamate and GABA Efflux in the mPFC and NAc ASE at 0.1 mg/kg had no significant effect on glutamate or GABA efflux in either the mPFC or NAc (data not shown).
DISCUSSION
The main findings of this study are the following: (1) ASE produced a dose-dependent increase in DA efflux in the mPFC and HIP; (2) ASE, at 0.5 mg/kg, but not at lower doses increased DA efflux in the NAc; (3) ASE dose dependently increased ACh efflux in the mPFC and HIP, but not in the NAc; (4) the effect of ASE on DA efflux in the mPFC and HIP was blocked by pretreatment with the 5-HT 1A antagonist/D 4 agonist, WAY100635; (5) ASE increased NE efflux in the mPFC and HIP, but had no effect on 5-HT efflux in either region, at the doses tested; and (6) ASE, at the same dose that significantly increased DA and NE efflux in the mPFC and HIP, had no effect on glutamate and GABA efflux in the mPFC or NAc. These results suggest that acute 
DA Efflux
Atypical antipsychotics have been reported to preferentially increase DA efflux in the mPFC and HIP compared with in the NAc in freely moving rats (Chung et al, 2004; Ichikawa et al, 2001; Kuroki et al, 1999) , compared with typical antipsychotic drugs. ASE, in this study, at doses less than 0.5 mg/kg, also showed preferential increase in cortical and HIP DA efflux compared with in the NAc. This action is due, in part, to blockade of 5-HT 2A receptors in the cerebral cortex and relatively weaker or negligible occupation of D 2 and D 1 receptors (Matsubara et al, 1993) , since it can be mimicked by the combination of potent 5-HT 2A antagonism and weak blockade of D 2 receptors (Liegeois et al, 2002; Bonaccorso et al, 2002; Li et al, 2005) . As reported by Schotte et al (1996) , these agents, including clozapine, risperidone, 9-hydroxyrisperidone (paliperidone), olanzapine, pipamperone, quetiapine, sertindole, ziprasidone, and zotepine, also have higher occupancy in the rat cortex and striatum of 5-HT 2A than D 2 receptors, respectively, at all but the highest doses studied. PET studies are also consistent with the view that at clinically relevant doses, those agents, which are direct acting antagonists of D 2 receptors, have higher occupancy of D 2 than 5-HT 2A receptors (Goyer et al, 1996; Nyberg et al, 1999; Gefvert et al, 2001; Kessler et al, 2005) . Aripiprazole, a partial D 2 receptor agonist, has a higher D 2 than 5-HT 2A receptor occupancy at clinical doses, but, nevertheless, has a weak functional effect to inhibit D 2 receptor stimulation (Mamo et al, 2007) . As mentioned under Introduction, diminished dopaminergic and noradrenergic function in the cortex and HIP have been implicated in the pathophysiology of cognitive impairment, negative symptoms, and perhaps depression in patients with schizophrenia (Meltzer and McGurk, 1999; Millan, 2006; Juckel et al, 2006) . Recent studies have clearly demonstrated the importance of increased cortical D 1 receptor stimulation for specific types of memory, including working memory and social memory (Castner and Williams, 2007; Nagai et al, 2007) , possibly by increasing the activity of pyramidal neurons, modulation of glutamate NMDA receptor signaling at critical nodes within local circuits and distributed networks (Castner and Williams, 2007) , fine tuning GABAergic interneurons (Kroner et al, 2007) , and enhancing the release of cortical ACh (Di Cara et al, 2007) . Thus, these effects on the efflux of cortical DA and NE may be clinically relevant to the treatment of schizophrenia (Ichikawa et al, 2001; Meltzer et al, 2003; Arnsten and Li, 2005) , as well as to the ability of these same agents, in combination with at least some antidepressant drugs, to be effective in patients with major depression who fail to respond to antidepressant drug treatment alone (Shelton et al, 2001) . The increased efflux of DA in the mPFC and HIP produced by antipsychotic drugs (eg, aripiprazole, clozapine, olanzapine, risperidone, ziprasidone) has been shown to be partially or completely (eg, quetiapine) blocked by the 5-HT 1A antagonist/D 4 receptor agonist WAY100635 in most (Ago et al, 2005; Chung et al, 2004; Ichikawa et al, 2001; Ichikawa and Meltzer, 2000; Li et al, 2004; Sprouse et al, 1999; Yoshino et al, 2004) , but not all (Assie et al, 2005) , studies. Although the recent demonstration of relatively potent D 4 agonist activity of WAY100635 (Chemel et al, 2006) complicates the interpretation of studies with this agent, the role of 5-HT 1A receptor agonism in mediating the effects of atypical antipsychotics on mPFC DA efflux is also supported by experiments in which the highly selective 5-HT 1A agonist, BAY Â 3702 (BAY; 10-40 mg/kg, i.v.), increased DA release in the mPFC. WAY100635 reversed the effects of BAY in both the areas. The atypical antipsychotics, clozapine, olanzapine, and ziprasidone (but not haloperidol), enhanced DA release in the mPFC of wild-type, but not 5-HT 1A -knockout, mice after systemic and local (clozapine and olanzapine) administration in the mPFC (Diaz-Mataix et al, 2005) . Local administration of WAY100635 into the mPFC of male rats blocks the effect of systemic clozapine on cortical DA release (Li et al, unpublished data) . ASE is similar to quetiapine (Ichikawa et al, 2002c) in that its ability to increase the efflux of cortical DA in rats was completely blocked by WAY100635. The clinical significance, if any, of this difference is unknown at present. The increase in cortical DA release produced by local injection of clozapine or olanzapine into the cortex was also abolished in 5-HT 1A -knockout mice (Diaz-Mataix et al, 2005) . Partial agonism at the 5-HT 1A receptor has been reported for some (eg, clozapine, quetiapine, ziprasidone), but not all, atypical antipsychotic drugs (eg, olanzapine and risperidone) (Meltzer et al, 2003) , a possible explanation for the blockade of the antipsychoticinduced DA efflux by WAY100635. Unlike clozapine, quetiapine, and ziprasidone (Meltzer et al, 2003) , ASE does not behave like a 5-HT 1A agonist in cloned cell preparations (Shahid et al, 2007) , nor does it enhance cortical 5-HT efflux at the doses tested. Thus, the mechanism by which ASE influences 5-HT 1A -receptor stimulation requires further investigation.
ASE significantly increased DA efflux in the NAc at the highest dose studied (0.5 mg/kg), but not at 0.05 mg/kg, which increased DA efflux in the mPFC and HIP. Atypical antipsychotic drugs, including clozapine and olanzapine, can increase DA efflux in the NAc, although the magnitude of the effect is significantly smaller than that produced in the mPFC (Ichikawa et al, 2002c; Kuroki et al, 1999; Shilliam and Dawson, 2005) . Shilliam and Dawson (2005) demonstrated that this increase was confined to the shell of the NAc and did not occur in the NAc core. We have previously shown that 5-HT 2C -receptor antagonism, in combination with D 2 -receptor antagonism, may contribute to the ability of these agents to enhance DA release in the NAc (Bonaccorso et al, 2002; Li et al, 2005) . The potent 5-HT 2C antagonist, SB242084, significantly potentiated low-dose haloperidolinduced increase in DA release in the NAc . The selective 5-HT 2C antagonists, SB206553 and SB242084, alone have been shown to increase DA efflux in both the mPFC and NAc (De Deurwaerdere and Spampinato, 2001; Di Matteo et al, 2001 Millan et al, 1998 Millan et al, , 2003 . As ASE is a very potent 5-HT 2C antagonist (pK i 10.46 ± 0.15; Shahid et al, 2007; Prinssen et al, 2000) , this may, at least in part, be involved in mediating its effects in the NAc. Occupancy of D 2 receptors may also contribute to the ability of ASE to enhance DA efflux in the NAc (Kuroki et al, 1999) . There is also some evidence that the increase in DA efflux produced by the atypical antipsychotic drugs is mediated, in part, by a 2A -adrenergic-receptor blockade (Blake et al, 1998; Bymaster et al, 1996; Gobert et al, 1998; Hertel et al, 1999; Millan et al, 2000; Wadenberg et al, 2007) , which may also contribute to the action of ASE in this regard, as it also an a 2A -adrenergic-receptor antagonist (Shahid et al, 2007) .
ACh Efflux
ASE preferentially increased ACh efflux in both the mPFC and HIP, but not in the NAc, which is also the case for clozapine, olanzapine, risperidone, quetiapine, and ziprasidone (Ichikawa et al, 2002a, b, c; Parada et al, 1997; ShiraziSouthall et al, 2002) . Muscarinic cholinergic receptors are unlikely to be important for this action, since, unlike clozapine or olanzapine, ASE has no appreciable affinity for these receptors (Shahid et al, 2007) . Indirect 5-HT 1A -receptor stimulation seems more likely to be important for this effect, since the increase in ACh induced by ASE is sensitive to blockade by WAY100635. This is similar to the profile of quetiapine (Ichikawa et al, 2002c) . It has recently been reported that systemic administration of risperidone, at 1 and 2 mg/kg, dose dependently increased ACh efflux in the rat mPFC; this increase was antagonized by systemic administration of high (1 and 3 mg/kg), but not by a lower dose (0.1 mg/kg) of WAY100635, which preferentially blocks presynaptic 5-HT 1A autoreceptors (Sato et al, 2007; Ago et al, 2003) . Local application of WAY100635 into the mPFC did not affect ACh release in the mPFC, but did attenuate risperidone-induced increases in ACh efflux (Sato et al, 2007) . Local application of neither risperidone (3 and 10 mM) and the 5-HT 1A -receptor agonist, L-750,667 (8-hydroxy-2-(di-n-propylamino)tetralin; 1 and 10 mM), nor the DA D 4 -receptor antagonist, 3-(4-(4-iodophenyl)piperazine-1-yl)methyl-1H-pyrrolo[2,3-b]pyridine (1 and 10 mM), into the mPFC affected ACh release in the mPFC (Sato et al, 2007) . Taken together, these results suggest that atypical antipsychotic drugs increase ACh efflux in the mPFC through a circuit, which includes prefrontal 5-HT 1A -receptor activation. Histamine H 1 and a 2 -adrenoceptor blockade have also been shown to enhance ACh release (Dringenberg et al, 1998; Tellez et al, 1997) , and, thus, may be also involved in ASE-induced ACh release in both mPFC and HIP.
NE and Serotonin Release
ASE, like other atypical antipsychotics, dose dependently increased NE release in the rat mPFC and HIP (Westerink et al, 1998) . ASE increased DA efflux in the mPFC at 0.05 mg/kg, but not NE. The increases in DA and NE efflux in the mPFC at 0.1 mg/kg were comparable. The effect on DA and NE efflux in the HIP were more similar. Increased NE efflux, rather than, or in addition to, DA efflux, may be important for the ability of atypical antipsychotic drugs to improve cognitive function in schizophrenia (Arnsten and Li, 2005; Rossetti and Carboni, 2005) . Increases in NE and DA release in the rat mPFC have been reported with 5-HT 1A -receptor agonists (Hajos-Korcsok et al, 1999; Owen and Whitton, 2003) ; the a 2 -adrenoceptor antagonists RS79948 (Devoto et al, 2004 ) and 1-(2-pyrimidinyl-piperazine) (Gobert et al, 1999) ; and the selective 5-HT 2C antagonist, SB242084 . As previously noted, ASE is a potent 5-HT 2C -receptor and a 2 -adrenoceptor antagonist (Schotte et al, 1996; Shahid et al, 2007) . A combination of these actions may mediate its ability to increase NE and DA efflux in the mPFC and HIP.
ASE did not affect 5-HT efflux in either the mPFC or HIP at the doses tested, despite its a 2 -adrenoceptor-antagonist properties. The a 2 -adrenoceptor antagonist, yohimbine, increased, and the a 2 -agonist, clonidine, decreased, the extracellular levels of 5-HT in the rat frontal cortex (Cheng et al, 1993) . One possible explanation for the lack of effect of ASE on 5-HT efflux is that the degree of a 2 -adrenoceptor block was insufficient at the doses used in the current study, but this seems unlikely in that it its affinity for the a 2 -adrenoceptoris identical to that for the D 2,l receptor. Alternatively, given the complex multireceptor profile of atypical antipsychotic drugs, the inability of ASE to elevate cortical 5-HT levels may results from action, which negates the effects of a 2 -adrenoceptor blockade. Indeed, risperidone has been reported in several studies to increase mPFC 5-HT release (Cartmell et al, 2001; Hertel et al, 1996; Ichikawa et al, 1998) , whereas clozapine and olanzapine do not. The lack of an increase in 5-HT efflux in the mPFC by ASE suggests that stimulation of 5-HT 1A receptors, which appears to be critical for its ability to enhance ACh and DA efflux, is not due to 5-HT efflux in this region. This is consistent with the evidence that local administration of the 5-HT 1A agonist, 8-OH-DPAT, did not enhance ACh efflux in the mPFC (Sato et al, 2007) .
Glutamate and GABA Efflux
In the present study, ASE did not alter extracellular glutamate and GABA levels in the mPFC, at a dose that did enhance DA, NE, and ACh efflux in that region. It also had no effect on glutamate or GABA efflux in the NAc. In this regard, it differs from clozapine, which significantly increased glutamate efflux in the rat mPFC (Daly and Moghaddam, 1993; Yamamoto and Cooperman, 1994) . It also differs from clozapine and haloperidol, which decreased basal GABA release in the mPFC (Bourdelais and Deutch, 1994) . These data indicate that modulation of cortical glutamate and GABA efflux does not represent a common action of antipsychotic drugs. The significance of these differences between antipsychotic drugs remains to be determined.
Both risperidone and clozapine have been reported to diminish GABA release in the globus pallidus (Grimm and See, 1998) . Clozapine has also been shown to dose dependently block phencyclidine-induced acute increases in glutamate efflux in the rat mPFC, as well as to block PCPinduced hyperlocomotion. Clozapine also attenuated acute increases in glutamate efflux in the mPFC induced by local perfusion with the competitive NMDA-receptor antagonist, CPP (Abekawa et al, 2006) . Further study of a broader dose range of ASE is required to assess the effects of ASE on glutamatergic mechanisms.
Conclusions
In conclusion, acute administration of ASE significantly increased cortical and hippocampal DA, NE, and ACh efflux in a dose-dependent and regionally selective manner, but had no effect on cortical and HIP 5-HT, glutamate, or GABA efflux. The effects on DA, NE, and ACh efflux are comparable to those previously reported with clozapine and quetiapine. Several key differences between clozapine and ASE were noted, including the ability of WAY100635 to block ACh efflux and the lack of an effect on cortical GABA and glutamate efflux. Overall, these results suggest ASE is an antipsychotic, which should improve cognition and negative symptoms in schizophrenia. Further study of its efficacy and side effect profile is clearly of interest.
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